You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Bexsero

Product menu

There's more me to be

Protect what you've achieved together with ZEJULA*

With efficacy and a safety profile demonstrated with 3.5 years of median follow-up, and quality of life comparable to placebo, ZEJULA may help make patients' time on maintenance about more than just their treatment.*1–4

*HRQoL was preserved in patients receiving ZEJULA throughout treatment (exploratory analysis; data cut-off: primary analysis), while delivering sustained PFS benefit vs. placebo at 3.5-year median follow-up (per investigator assessment, ad hoc analysis).2–5

Headline

Hypothetical patient who is a candidate for ZEJULA.

Find out more about how ZEJULA works

CLICK HERE
Hypothetical patient who is a candidate for ZEJULA.

Discover the Phase III PRIMA and PRIME studies

FIND OUT MORE
Hypothetical patient who is a candidate for ZEJULA.

Watch videos of external experts opinion about Zejula

 

 

Watch now
Hypothetical patient who is a candidate for ZEJULA.

Access patient support materials

CLICK HERE

All imagery shown depicts hypothetical patients only.

Zejula Safety Information1:

Contraindications:
Hypersensitivity to the active substances or to any of the excipients.

Special warnings and precautions:
Haematologic adverse reactions (thrombocytopenia, anaemia, neutropenia) have been reported. Discontinue if a patient develops severe persistent haematologic toxicity including pancytopenia that does not resolve within 28 days following interruption.
Use with caution in patients on anticoagulants and medicinal products known to reduce the thrombocyte count hypertension, hepatic impairment.

Pregnancy/contraception:
Should not be used during pregnancy.

Adverse Events:
Very common: Urinary Tract Infections, thrombocytopenia, anaemia, neutropenia, leukopenia, decreased appetite, insomnia.

Please refer to the local prescribing information for a more detailed safety information.

Abbreviations

FIGO, International Federation of Gynecology and Obstetrics; HRQoL, health-related quality of life; PFS, progression free survival.

References

  1. Zejula prescribing information
  2. González-Martín A, et al. N Engl J Med. 2019;381(25):2391–2402. Supplementary appendix.
  3. González-Martín A, et al. Eur J Cancer. 2023; 189:112908.
  4. Barretina-Ginesta M-P, et al. Ther Adv Med Oncol. 2022;14:1–13.
  5. González-Martín A, et al. N Engl J Med. 2019;381(25):2391–2402.

For more information, please refer to the prescribing information or contact GlaxoSmithKline via gcc.medinfo@gsk.com
To report Adverse Event/s associated with the use of GSK product/s, please contact us via
gulf.safety@gsk.com
To report quality complaint/s associated with the use of GSK product/s, please contact us via
 Gulf.ProductQualityComplaints@gsk.com

Department of Pharmacovigilance & Drug Information
Drug Safety Center
Ministry of Health, Sultanate of Oman
Phone Nos. 0096822357687 / 0096822357690
Fax: 0096822358489
Email: pharma-vigil@moh.gov.om
Website: www.moh.gov.om

 دائرة التيقظ و المعلومات الدوائية
مركز سلامة الدواء
وزارة الصحة, سلطنة عمان
هاتف: 0096822357687 / 0096822357690
0096822358489 :فاكس
pharma-vigil@moh.gov.om :البريد االكتروني
www.moh.gov.om : الموقع االكتروني

Trademarks are owned by or licensed to the GSK group of companies.
©2024 GSK group of companies or its licensor. All rights reserved. 

PM-RCH-NRP-SRCH-240001 | August 2024